<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJL</journal-id>
<journal-id journal-id-type="hwp">spijl</journal-id>
<journal-id journal-id-type="nlm-ta">Int J Low Extrem Wounds</journal-id>
<journal-title>The International Journal of Lower Extremity Wounds</journal-title>
<issn pub-type="ppub">1534-7346</issn>
<issn pub-type="epub">1552-6941</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1534734612438549</article-id>
<article-id pub-id-type="publisher-id">10.1177_1534734612438549</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Madura Foot</article-title>
<subtitle>Looking Deep</subtitle>
</title-group>
<contrib-group content-type="issue">
<contrib contrib-type="guest-editor">
<name><surname>Lazarides</surname><given-names>Miltos K.</given-names></name>
<degrees>MD, PhD</degrees>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Venkatswami</surname><given-names>Sandhya</given-names></name>
<degrees>MBBS, MD</degrees>
<xref ref-type="aff" rid="aff1-1534734612438549">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sankarasubramanian</surname><given-names>Anandan</given-names></name>
<degrees>MD, DD</degrees>
<xref ref-type="aff" rid="aff1-1534734612438549">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Subramanyam</surname><given-names>Shobana</given-names></name>
<degrees>MD, DD</degrees>
<xref ref-type="aff" rid="aff1-1534734612438549">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1534734612438549"><label>1</label>Sri Ramachandra University, Chennai, India</aff>
<author-notes>
<corresp id="corresp1-1534734612438549">Sandhya Venkatswami, Department of Dermatology, Venereology and Leprosy, Sri Ramachandra University, New No. 14, Raghavaveer Avenue, Porur, Chennai 600086, India Email: <email>sandhyavenkatswami@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>11</volume>
<issue>1</issue>
<issue-title>Special Issue on Lymphedema</issue-title>
<fpage>31</fpage>
<lpage>42</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>“Mycetoma” means a fungal tumor. Mycetoma is a chronic, granulomatous, subcutaneous tissue infection caused by both bacteria (actinomycetoma) and fungi (eumycetoma). This chronic infection was termed <italic>Madura foot</italic> and eventually <italic>mycetoma</italic>, owing to its etiology. Inoculation commonly follows minor trauma, predominantly to the foot and hence is seen more among the barefoot-walking populations, common among adult males aged 20 to 50 years. The hallmark triad of the disease includes tumefaction, fistulization of the abscess, and extrusion of colored grains. The color of these extruded grains in the active phase of the disease offers a clue to diagnosis. Radiology, ultrasonology, cytology, histology, immunodiagnosis, and culture are tools used in diagnosis. Recently, DNA sequencing has also been used successfully. Though both infections manifest with similar clinical findings, Actinomycetoma has a rapid course and can lead to amputation or death secondary to systemic spread. However, actinomycetomas are more responsive to antibiotics, whereas eumycetomas require surgical excision in addition to antifungals. Complications include secondary bacterial infections that can progress to full-blown bacteremia or septicemia, resulting in death. With extremely disfiguring sequelae, following the breakdown of the nodules and formation of discharging sinuses, it poses a therapeutic challenge.</p>
</abstract>
<kwd-group>
<kwd>subcutaneous infections</kwd>
<kwd>management</kwd>
<kwd>radiological changes</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1534734612438549">
<title>History</title>
<p>The oldest description of this disease appears to date back to the ancient Indian Sanskrit text <italic>Atharva Veda</italic>, in which reference is made to <italic>pada valmikam</italic>, translated to mean “anthill foot.”<sup><xref ref-type="bibr" rid="bibr1-1534734612438549">1</xref></sup> The history of mycetoma dates as far back as the Byzantine period (<sc>ad</sc> 300-600).<sup><xref ref-type="bibr" rid="bibr2-1534734612438549">2</xref></sup> Tlatilco culture flourished in the Mexico Valley between the years 1250 <sc>bc</sc> and 800 <sc>bc</sc>. A case of mycetoma (osteophylic mycotic disease) was found in their skeletal collection.<sup><xref ref-type="bibr" rid="bibr3-1534734612438549">3</xref></sup> First reported by Gill in 1832, for the unusual nodular appearance of the leg among the field-workers in the Madurai district of Tamil Nadu, India, it was named Madura foot in 1846 by Colebrook. In 1860, Carter named the condition mycetoma, describing its fungal etiology. In 1913, Pinoy described the mycetoma produced by aerobic bacteria that belong to the actinomycete group.<sup><xref ref-type="bibr" rid="bibr4-1534734612438549">4</xref></sup></p>
<p>It was also referred to by other names at various times<sup><xref ref-type="bibr" rid="bibr5-1534734612438549">5</xref></sup>: morbus <italic>Tuberculosis pedis</italic>, fungus disease of India, Godfrey and Eyre’s disease, endemic degeneration of the bones of the foot, fungus foot, morbus pedis entophyticus-affection singuliere, and perforating ulcer of the foot.</p>
</sec>
<sec id="section2-1534734612438549">
<title>Epidemiology</title>
<p>Native of the tropical, subtropical, and equatorial areas, the condition is seen in the belt between latitudes 30°N and 15°S commonly called “the mycetoma belt.”<sup><xref ref-type="bibr" rid="bibr6-1534734612438549">6</xref></sup> The belt includes Sudan, Somalia, Senegal, India, Yemen, Mexico, Venezuela, Columbia, Argentina, and other countries.<sup><xref ref-type="bibr" rid="bibr7-1534734612438549">7</xref></sup> In Sudan, the mycetoma homeland in the subtropics, 300 to 400 patients are diagnosed with mycetoma every year.<sup><xref ref-type="bibr" rid="bibr5-1534734612438549">5</xref></sup> Central and South America and the middle or Far East between the latitudes 15°S and 30°N also harbor mycetoma. Increased worldwide travel has increased the incidence in temperate zones as well.<sup><xref ref-type="bibr" rid="bibr8-1534734612438549">8</xref></sup></p>
<p>Mycoses are not notifiable in the United Kingdom; hence the incidence is unknown. Diagnosis of mycetoma in such uncommon locations requires a high degree of suspicion.<sup><xref ref-type="bibr" rid="bibr9-1534734612438549">9</xref></sup> Mycetoma can also be uncommon in tropical areas such as Tunisia.<sup><xref ref-type="bibr" rid="bibr10-1534734612438549">10</xref></sup> In India, maduromycotic mycetoma is commonest in western Rajasthan, but the ratio of prevalence of maduromycotic mycetoma to actinomycotic mycetoma has reduced from 4:1 to 1.9:1.<sup><xref ref-type="bibr" rid="bibr11-1534734612438549">11</xref></sup> Red grain mycetoma caused by <italic>Actinomadura pelletieri</italic> is rare in Asia.<sup><xref ref-type="bibr" rid="bibr12-1534734612438549">12</xref></sup> El Muttardi et al<sup><xref ref-type="bibr" rid="bibr9-1534734612438549">9</xref></sup> and Malone et al<sup><xref ref-type="bibr" rid="bibr13-1534734612438549">13</xref></sup> also noted sporadic cases in the Western world, especially the United States. In 1981, <italic>Actinomadura madurae</italic> infection was reported in the United States.<sup><xref ref-type="bibr" rid="bibr14-1534734612438549">14</xref></sup></p>
<p>Environmental factors such as rainfall play an important role in the distribution of this condition. According to Mathur et al,<sup><xref ref-type="bibr" rid="bibr11-1534734612438549">11</xref></sup> annual rainfall, nature of the soil, and presence of abundant sharp thorny vegetable matter influence the prevalence of the causative agents. Eumycetoma is more common in north India, with average rainfall less than 350 mm; whereas actinomycetoma is common in south India, with more than 600 mm of rainfall.<sup><xref ref-type="bibr" rid="bibr11-1534734612438549">11</xref>,<xref ref-type="bibr" rid="bibr15-1534734612438549">15</xref></sup> Arid hot areas, with prolonged hot sunshine and scanty annual rainfall of 250 to 350 mm, are home to maduramycotic mycetomas.<sup><xref ref-type="bibr" rid="bibr6-1534734612438549">6</xref></sup> Fungal grains grow in drier areas and actinomyces in the wet areas.<sup><xref ref-type="bibr" rid="bibr16-1534734612438549">16</xref></sup></p>
</sec>
<sec id="section3-1534734612438549">
<title>Causative Organisms</title>
<p>Thirty or more species of bacteria and fungi responsible for mycetoma have been identified. Etiologic agents include actinomycetes, eumycetes, eubacteria, and dermatophytes.<sup><xref ref-type="bibr" rid="bibr17-1534734612438549">17</xref></sup></p>
<p>The etiological agents vary between regions. In northwest India <italic>M mycetomatis</italic> accounts for the maximum number of cases, followed by <italic>M grisea</italic> and <italic>Aspergillus nidulans</italic>. Mixed infection by both <italic>M mycetomatis</italic> and <italic>M grisea</italic> has been observed.<sup><xref ref-type="bibr" rid="bibr6-1534734612438549">6</xref></sup> In Sudan. <italic>M mycetomatis</italic> accounts for 70% of the infections.<sup><xref ref-type="bibr" rid="bibr18-1534734612438549">18</xref></sup> Eumycetomas were secondary to <italic>M mycetomatis, Leptosphaeria senegalensis, Pseudallescheria boydii</italic>, and <italic>Rhinoclediella atrovirensi</italic>.<sup><xref ref-type="bibr" rid="bibr16-1534734612438549">16</xref></sup> <italic>P boydii</italic> (<italic>Scedosporium apiospermum</italic>) is the most common cause of mycetoma in the United States.<sup><xref ref-type="bibr" rid="bibr13-1534734612438549">13</xref></sup> In south India, eumycetomas were secondary to <italic>M mycetomatis, Neoscytalidium dimidiatum</italic>, and <italic>Aspergillus flavus</italic>.</p>
<p>In Mexico City, the common etiologic agents were <italic>Nocardia brasiliensis, Nocardia asteroides</italic>, and <italic>M mycetomatis</italic>.<sup><xref ref-type="bibr" rid="bibr10-1534734612438549">10</xref></sup> However, in Senegal from 1983 to 2000, <italic>Actinomadura pelletieri</italic> was the commonest, in addition to <italic>Actinomadura madurae</italic> and <italic>Streptomyces somaliensis. Neoscytalidium dimidiatum</italic> and <italic>A flavus</italic> were unusual pathogens.<sup><xref ref-type="bibr" rid="bibr19-1534734612438549">19</xref></sup> See <xref ref-type="table" rid="table1-1534734612438549">Table 1</xref>.</p>
<table-wrap id="table1-1534734612438549" position="float">
<label>Table 1.</label>
<caption>
<p>Commonly Implicated Organisms in the Etiology of Mycetoma and Their Grain Color</p>
</caption>
<graphic alternate-form-of="table1-1534734612438549" xlink:href="10.1177_1534734612438549-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Type of Organism</th>
<th align="center">Grain Color</th>
<th align="center">Grain Texture</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">Fungi (septate hyphae 4-5 µm thick)</td>
</tr>
<tr>
<td> <italic>Madurella mycetomatis</italic></td>
<td>Dark grain</td>
<td>Hard grains</td>
</tr>
<tr>
<td> <italic>Madurella grisea</italic></td>
<td>Dark grain</td>
<td>Hard grains</td>
</tr>
<tr>
<td> <italic>Leptosphaeria senegalensis</italic></td>
<td>Dark grain</td>
<td>Hard grains</td>
</tr>
<tr>
<td> <italic>Curvularia lunata</italic></td>
<td>Dark grain</td>
<td>Hard grains</td>
</tr>
<tr>
<td> <italic>Scedosporium apiospermum</italic></td>
<td>Pale grain</td>
<td>Soft grains</td>
</tr>
<tr>
<td> <italic>Neotestudina rosatii</italic></td>
<td>Pale grain</td>
<td>Soft grains</td>
</tr>
<tr>
<td> <italic>Acremonium</italic> spp</td>
<td>Pale grain</td>
<td>Soft grains</td>
</tr>
<tr>
<td> <italic>Fusarium</italic> spp</td>
<td>Pale grain</td>
<td>Soft grains</td>
</tr>
<tr>
<td colspan="3">Actinomycetes (fine, branching filaments, 1 µm thick)</td>
</tr>
<tr>
<td> <italic>Actinomadura madurae</italic></td>
<td>White grains</td>
<td/>
</tr>
<tr>
<td> <italic>Actinomadura pelletieri</italic></td>
<td>Red grains</td>
<td/>
</tr>
<tr>
<td> <italic>Streptomyces somaliensis</italic></td>
<td>Yellow grains</td>
<td/>
</tr>
<tr>
<td> <italic>Nocardia brasiliensis</italic></td>
<td/>
<td/>
</tr>
<tr>
<td> <italic>Nocardia asteroids</italic></td>
<td/>
<td/>
</tr>
<tr>
<td> <italic>Nocardia otitidis caviarum</italic></td>
<td/>
<td/>
</tr>
</tbody>
</table>
</table-wrap>
<p>Other organisms implicated were <italic>Cylindrocarpon destructans</italic><sup><xref ref-type="bibr" rid="bibr20-1534734612438549">20</xref></sup> and <italic>Fusarium solani</italic>.<sup><xref ref-type="bibr" rid="bibr21-1534734612438549">21</xref><xref ref-type="bibr" rid="bibr22-1534734612438549"/>-<xref ref-type="bibr" rid="bibr23-1534734612438549">23</xref></sup> An unusual Nocardia species, <italic>N veterana</italic>, was the first human pathogen in a clinical setting.<sup><xref ref-type="bibr" rid="bibr24-1534734612438549">24</xref>,<xref ref-type="bibr" rid="bibr25-1534734612438549">25</xref></sup></p>
</sec>
<sec id="section4-1534734612438549">
<title>Pathogenesis</title>
<p>Following inoculation of organisms, through thorn pricks or preexisting abrasions or trauma, these nonpathogens grow and survive through the production of grains. The matrix material is host derived along with some pathogens. Cells of the innate immune system attempt to engulf and inactivate the microorganisms. Abscesses containing grains are seen in association with granulomatous inflammation and fibrosis. This host response does not appear to be able to control infection.<sup><xref ref-type="bibr" rid="bibr1-1534734612438549">1</xref></sup></p>
<p>No immune compromise has been documented prior to the onset of the disease. Genetic studies have identified polymorphisms linked with neutrophil function. It has been suggested that the greater frequency of disease in men is not completely explained by increased frequency of exposure to soil and plant material.<sup><xref ref-type="bibr" rid="bibr26-1534734612438549">26</xref></sup></p>
<p>Progesterone has been shown in vitro to inhibit the growth of <italic>M mycetomatis, P romeroi</italic>, and <italic>N brasiliensis</italic>. In the study of <italic>N brasiliensis</italic>, estradiol limited disease produced in animals.<sup><xref ref-type="bibr" rid="bibr1-1534734612438549">1</xref>,<xref ref-type="bibr" rid="bibr27-1534734612438549">27</xref></sup></p>
<p>Eumycetoma lesions are well vascularized. Hypoxia inducible factor 1 (HIF-1) regulates the transcription of vascular endothelial growth factor and adrenomedullin, 2 proangiogenic factors. Expression of HIF-1α protein was found to be upregulated in the fungal-infested tissue. These findings denote an important role of HIF-1 in the vascularization of eumycetoma lesion caused by <italic>M mycetomatis</italic>, which is upregulated by an oxygen-independent mechanism in the lesion.<sup><xref ref-type="bibr" rid="bibr28-1534734612438549">28</xref></sup> A flowchart for diagnosis and management is shown in <xref ref-type="fig" rid="fig1-1534734612438549">Figure 1</xref>.</p>
<fig id="fig1-1534734612438549" position="float">
<label>Figure 1.</label>
<caption>
<p>Flowchart for diagnosis and management</p>
</caption>
<graphic xlink:href="10.1177_1534734612438549-fig1.tif"/></fig>
</sec>
<sec id="section5-1534734612438549">
<title>Clinical Features</title>
<p>Mycetoma is a chronic infection of exogenous origin, usually presenting as multiple nodules, with oozing and colored granules in the pus.<sup><xref ref-type="bibr" rid="bibr6-1534734612438549">6</xref>,<xref ref-type="bibr" rid="bibr10-1534734612438549">10</xref></sup> The varying colors are black, yellow, and white.<sup><xref ref-type="bibr" rid="bibr29-1534734612438549">29</xref>,<xref ref-type="bibr" rid="bibr30-1534734612438549">30</xref></sup></p>
<p>The incubation period varies from several weeks to months.<sup><xref ref-type="bibr" rid="bibr31-1534734612438549">31</xref></sup> The incubation period is long and asymptomatic. Complaints of minimal pain are not uncommon. The infection spreads under the skin and forms subcutaneous abscesses.<sup><xref ref-type="bibr" rid="bibr32-1534734612438549">32</xref></sup> Sinuses develop after 6 to 12 months and extend to involve the underlying fascia, muscle, and bone. See <xref ref-type="fig" rid="fig2-1534734612438549">Figure 2</xref>.</p>
<fig id="fig2-1534734612438549" position="float">
<label>Figure 2.</label>
<caption>
<p>The diagnostic triad</p>
</caption>
<graphic xlink:href="10.1177_1534734612438549-fig2.tif"/></fig>
<p>Tumefaction refers to the tumor-like mass that develops following the long and asymptomatic incubation period. Disease begins as a single, small, painless subcutaneous nodule. This nodule slowly increases in size, becomes fixed to the underlying tissue, and ultimately develops sinus tracts beneath the lesion. These tracts open to the surface and drain purulent material with grains. Grains are several millimeters in diameter and may be seen by close inspection of a gauze bandage covering the sinus tract. Progression to draining sinus tracts can take weeks, months, and even years, occurring more rapidly in actinomycetoma.<sup><xref ref-type="bibr" rid="bibr33-1534734612438549">33</xref><xref ref-type="bibr" rid="bibr34-1534734612438549"/>-<xref ref-type="bibr" rid="bibr35-1534734612438549">35</xref></sup></p>
<p>Common <italic>risk factors</italic> for acquiring the fungal infection are the following:</p>
<list id="list1-1534734612438549" list-type="bullet">
<list-item><p>A <italic>minor trauma</italic> due to a thorn prick or abrasion inoculates the organism into the skin<sup><xref ref-type="bibr" rid="bibr6-1534734612438549">6</xref>,<xref ref-type="bibr" rid="bibr10-1534734612438549">10</xref>,<xref ref-type="bibr" rid="bibr11-1534734612438549">11</xref></sup></p></list-item>
<list-item><p>People walking <italic>barefoot</italic><sup><xref ref-type="bibr" rid="bibr10-1534734612438549">10</xref></sup></p></list-item>
<list-item><p>Individuals in the <italic>age-group of 21 to 30</italic> years are at high risk, because of the need to go out and work in the open environment</p></list-item>
<list-item><p><italic>Men</italic> are more commonly affected (sex ratio 1.61:1)<sup><xref ref-type="bibr" rid="bibr6-1534734612438549">6</xref></sup></p></list-item>
<list-item><p><italic>Agricultural work</italic> and <italic>farming</italic> are high-risk occupations<sup><xref ref-type="bibr" rid="bibr6-1534734612438549">6</xref></sup></p></list-item>
<list-item><p><italic>Environmental factors</italic>: rainfall, temperature, soil, thorny sharp vegetable material</p></list-item>
<list-item><p><italic>Social factors</italic>: walking barefoot and/or carrying goods on the back<sup><xref ref-type="bibr" rid="bibr6-1534734612438549">6</xref>,<xref ref-type="bibr" rid="bibr16-1534734612438549">16</xref></sup></p></list-item>
<list-item><p><italic>Homelessness</italic><sup><xref ref-type="bibr" rid="bibr13-1534734612438549">13</xref></sup></p></list-item>
<list-item><p><italic>AIDS patients</italic><sup><xref ref-type="bibr" rid="bibr13-1534734612438549">13</xref></sup></p></list-item>
<list-item><p><italic>Immunocompromised</italic> individuals, for example, post–renal transplant patients<sup><xref ref-type="bibr" rid="bibr36-1534734612438549">36</xref></sup> and diabetic patients<sup><xref ref-type="bibr" rid="bibr13-1534734612438549">13</xref></sup> may develop invasive infection</p></list-item>
</list>
<p><italic>Actinomycotic mycetomas</italic> expand fast, are invasive, and have more sinuses than eumycotic variants.<sup><xref ref-type="bibr" rid="bibr31-1534734612438549">31</xref></sup> Atypical presentations without grains in the discharge or sinuses have been reported due to <italic>M mycetomatis</italic>.<sup><xref ref-type="bibr" rid="bibr36-1534734612438549">36</xref>,<xref ref-type="bibr" rid="bibr37-1534734612438549">37</xref></sup></p>
<p>Following a minor trauma, painless swellings develop after a prolonged and asymptomatic incubation period, with intermittent discharge of pus. A study conducted in Senegal of 130 patients revealed that they consulted for restricted movement or pain secondary to the expanding tumor on an average 4.8 to 5.6 years after inoculation.<sup><xref ref-type="bibr" rid="bibr16-1534734612438549">16</xref></sup> Persisting pain due to bone invasion or secondary bacterial infection (SBI) is common.<sup><xref ref-type="bibr" rid="bibr38-1534734612438549">38</xref></sup> Tumoral or pseudocystic presentations have been reported due to <italic>A pelletieri</italic>.<sup><xref ref-type="bibr" rid="bibr39-1534734612438549">39</xref></sup></p>
<p>Fahal and Hasan<sup><xref ref-type="bibr" rid="bibr40-1534734612438549">40</xref></sup> and Diallo et al<sup><xref ref-type="bibr" rid="bibr39-1534734612438549">39</xref></sup> noted that the commonest site of occurrence is the foot in 70% and 80% of the cases, respectively. (Fahal, 2004) Hand is the next most common site.<sup><xref ref-type="bibr" rid="bibr31-1534734612438549">31</xref></sup> Bedi et al<sup><xref ref-type="bibr" rid="bibr12-1534734612438549">12</xref></sup> in 1978 reported the first case of red grain mycetoma on the scalp, in India. Axillary and thoracocervical lesions have occurred.<sup><xref ref-type="bibr" rid="bibr12-1534734612438549">12</xref></sup> Nonvenereal, perineal lesions,<sup><xref ref-type="bibr" rid="bibr41-1534734612438549">41</xref></sup> slow-growing facial swellings, subcutaneous frontal skull swelling, proptosis, nasal blockage, epistaxis, discharging leg sinuses, flank mass, convulsion, and pain have also been presenting complaints.<sup><xref ref-type="bibr" rid="bibr42-1534734612438549">42</xref></sup> Mycetoma is uncommon in children.<sup><xref ref-type="bibr" rid="bibr10-1534734612438549">10</xref></sup> Lymphatic spread occurs rarely.</p>
</sec>
<sec id="section6-1534734612438549">
<title>Diagnosis</title>
<p>Diagnosis of mycetoma requires a detailed clinical history and physical examination (see <xref ref-type="app" rid="app1-1534734612438549">Appendix</xref>). Particular attention should be given to the duration of the disease, the presence of sinuses, discharge of grains, and color of the grains, the presence or absence of pain, and involvement of the regional lymph nodes. X-ray and laboratory tests help confirm the diagnosis. Cultures are the gold standard in the diagnosis and management of mycetoma. Rarely, when cultures are falsely negative, actinomycetoma can be diagnosed on clinical and histopathological grounds.<sup><xref ref-type="bibr" rid="bibr10-1534734612438549">10</xref>,<xref ref-type="bibr" rid="bibr36-1534734612438549">36</xref>,<xref ref-type="bibr" rid="bibr43-1534734612438549">43</xref>,<xref ref-type="bibr" rid="bibr44-1534734612438549">44</xref></sup></p>
</sec>
<sec id="section7-1534734612438549">
<title>Investigations</title>
<sec id="section8-1534734612438549">
<title>Ultrasonic Imaging of Mycetoma</title>
<p>Characteristic features include numerous, isolated sharp hypereflective echoes corresponding to the grains in the lesion in eumycetoma. In actinomycetoma, the grains are less distinct because of their smaller size and consistency. The technique is safe, simple, accurate, and useful in planning surgical treatment.</p>
</sec>
<sec id="section9-1534734612438549">
<title>Fine Needle Aspiration Cytology of Mycetoma</title>
<p>Cytology shows polymorphous inflammatory cells consisting of a mixture of neutrophils, lymphocytes, plasma cells, histiocytes, macrophages, and foreign-body giant cells and grains. In sections, the grain is closely surrounded by neutrophils, causing fragmentation. Surrounding this, monocytic cells and giant cells are seen. This is surrounded by granulation tissue rich in fibroblasts and blood vessels. The technique is simple and sensitive and can be tolerated by patients.<sup><xref ref-type="bibr" rid="bibr45-1534734612438549">45</xref></sup></p>
</sec>
<sec id="section10-1534734612438549">
<title>Microbiology</title>
<p>The grains are the source of the culture, and they should be alive and free of contaminants. They are obtained by deep surgical biopsy, inserting sterile cotton swabs into the sinus tracts or percutaneous aspiration of closed or inactive fistulae. Grains should be sent immediately in sterile containers to the laboratory for culture. Culture media include Sabouraud, blood agar, malt extract agar, MacConkey agar, and mannitol salt agar plates, and the culture is incubated aerobically at 37°C for 24 hours.<sup><xref ref-type="bibr" rid="bibr46-1534734612438549">46</xref></sup> Actinomycetes take 48 to 72 hours to grow on culture plates. Therefore, it is essential to mention on the request form the need for the culture and the organism suspected.<sup><xref ref-type="bibr" rid="bibr47-1534734612438549">47</xref></sup></p>
</sec>
<sec id="section11-1534734612438549">
<title>Histopathology</title>
<p>Multiple sections of deep biopsies, including the subcutaneous tissue, should be taken from areas with purulent discharge. A diagnostic finding would be the presence of 5 to 7 grains per cavity, walled by fibrous tissue.</p>
<list id="list2-1534734612438549" list-type="simple">
<list-item><p><italic>Eumycetoma</italic>: Sections from indurated skin show extensive granulation tissue containing abscesses, leading to sinuses. A neutrophil zone surrounds the grains, forming granulomas.<sup><xref ref-type="bibr" rid="bibr48-1534734612438549">48</xref></sup> These granulomas are surrounded by palisading histiocytes beyond which a mixed inflammatory infiltrate comprising lymphocytes, plasma cells, eosinophils, macrophages, and fibroblasts is seen. The occasional multinucleated giant cell was also seen.<sup><xref ref-type="bibr" rid="bibr8-1534734612438549">8</xref></sup> Later, fibroblasts predominate.</p></list-item>
<list-item><p><italic>Actinomycetoma</italic>: Chronic abscess with polymorphs surrounding granulation tissue and fibrosis is seen. Organisms form matted colonies (granules or grains).These sulfur granules maybe 20 µm to 4 mm in diameter. They are gram-positive. The peripheral filaments often terminate in a club. A Splendore–Hoeppli reaction may be found around the grain. (Homogeneous, eosinophilic material coats the grains.)</p></list-item></list>
<p>In 1908 Splendore and in 1932 Hoeppli individually described eosinophilic coating of microorganisms visible on histological study. Subsequent descriptions refer to the Splendore–Hoeppli phenomenon, which may appear as radiating eosinophilic spokes or as thick eosinophilic rings. The Splendore–Hoeppli phenomenon has been reported in association with a variety of fungal and parasitic infections (especially by helminths and schistosoma eggs) and is particularly striking in actinomycosis, mycetoma, and botryomycosis.</p>
<p>They represent antigen–antibody precipitates with immunoglobulin; the third component of complement; cellular debris from plasma cells, macrophages, lymphocytes, and eosinophils; and eosinophil granule major basic protein, which constitutes the core of the granule and is toxic to the microorganisms. The immunoglobulin component of the eosinophilic matrix presumably represents a localized attempt at containment on the part of the host. Whether this degree of immunological responsiveness is ultimately helpful or harmful to the host remains to be elucidated</p>
<p>The grain morphology of some commonly isolated organisms is as follows (see <xref ref-type="fig" rid="fig3-1534734612438549">Figures 3</xref>-<xref ref-type="fig" rid="fig5-1534734612438549">5</xref>):</p>
<list id="list3-1534734612438549" list-type="simple">
<list-item><p><italic>Madurella mycetomatis</italic>: Large granules (5 mm or more) with interlacing hyphae embedded in interstitial brownish matrix; hyphae peripherally arranged radially with numerous chlamydospores</p></list-item>
<list-item><p><italic>Petriellidium boydii</italic>: Eosinophilic, lighter in the center; numerous vesicles/swollen hyphae; peripheral eosinophilic fringe; other pale eumycetomas have a minimal fringe and contain a dense mass of intermeshing hyphae</p></list-item>
<list-item><p><italic>Actinomadura madurae</italic>: Large (1-5 mm and large) and multilobulate; peripheral basophilia and central eosinophilia or pale staining; filaments grow from the peripheral zone</p></list-item>
<list-item><p><italic>Streptomyces somaliensis</italic>: Large (0.5-2 mm or more) with dense thin filaments; often stains homogeneously; transverse fracture lines</p></list-item>
<list-item><p><italic>Nocardia brasiliensis</italic>: Small grains (approximately 1 mm); central purple zone; loose clumps of filaments; gram-positive delicate branching filaments breaking up into bacillary and coccal forms; gram-negative amorphous matrix<sup><xref ref-type="bibr" rid="bibr8-1534734612438549">8</xref></sup></p></list-item>
</list>
<fig id="fig3-1534734612438549" position="float">
<label>Figure 3.</label>
<caption>
<p>Actinomycetoma: Section showing filamentous aggregates of actinomycetes surrounded by scattered inflammatory cells (hematoxylin and eosin, ×200)</p>
</caption>
<graphic xlink:href="10.1177_1534734612438549-fig3.tif"/></fig>
<fig id="fig4-1534734612438549" position="float">
<label>Figure 4.</label>
<caption>
<p>Eumycetoma: Pigmented fungus with Splendore–Hoeppli reaction (hematoxylin and eosin, ×200)</p>
</caption>
<graphic xlink:href="10.1177_1534734612438549-fig4.tif"/></fig>
<fig id="fig5-1534734612438549" position="float">
<label>Figure 5.</label>
<caption>
<p>Eumycetoma: Gomori methanamine silver stain showing positive staining for the fungus (×100)</p>
</caption>
<graphic xlink:href="10.1177_1534734612438549-fig5.tif"/></fig>
<p>Gram staining is useful in differentiation.<sup><xref ref-type="bibr" rid="bibr8-1534734612438549">8</xref>,<xref ref-type="bibr" rid="bibr22-1534734612438549">22</xref>,<xref ref-type="bibr" rid="bibr35-1534734612438549">35</xref></sup> Dark (black) grains are found only among the eumycotic mycetoma, because of the pigment melanoprotein.<sup><xref ref-type="bibr" rid="bibr49-1534734612438549">49</xref></sup> The gram stain is more useful in actinomycetoma, and Gomori methenamine silver and periodic acid-Schiff stains are better in eumycetoma.<sup><xref ref-type="bibr" rid="bibr23-1534734612438549">23</xref></sup> Staining with lactophenol blue allows differentiation between the thin and thick filaments.<sup><xref ref-type="bibr" rid="bibr35-1534734612438549">35</xref></sup></p>
<p>Stained sections usually show three types of tissue reaction to the organisms:</p>
<list id="list4-1534734612438549" list-type="simple">
<list-item><p>Type I: The grain is surrounded and invaded by neutrophil infiltrate</p></list-item>
<list-item><p>Type II: A vascular layer containing foamy macrophages, lymphocytes, plasma cells, and giant cells containing fragments of the grain</p></list-item>
<list-item><p>Type III: Formation of pure epithelioid granuloma</p></list-item></list>
<p>Biopsies are usually fixed in 10% formal saline.<sup><xref ref-type="bibr" rid="bibr50-1534734612438549">50</xref></sup></p>
</sec>
<sec id="section12-1534734612438549">
<title>Serodiagnosis in Mycetoma</title>
<p>Serodiagnosis is of great help in identification and classification of the various organisms.</p>
<list id="list5-1534734612438549" list-type="order">
<list-item><p><italic>Counterimmunoelectrophoresis</italic>: A laboratory technique used to evaluate antigen antibody binding. It is similar to immunodiffusion but with the addition of an applied electrical field across the diffusion medium, usually an agar or polyacrylamide gel. The effect is rapid migration of the antibody and antigen out of their respective wells toward one another to form a line of precipitation, or a precipitin line, indicating binding.</p></list-item>
<list-item><p><italic>Immunodiffusion</italic>: A technique involving diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, resulting in a precipitin reaction. Precipitin lines or bands form where the concentration of an antigen and antibody are serologically equivalent.</p></list-item>
<list-item><p>Enzyme-linked immunosorbent assay (ELISA): A simple and highly sensitive assay based on the specific recognition of the target compound (analyte/antigen) by antibodies that bind to the compound. The antigen–antibody complex is detected with the aid of an enzyme-labeled antibody or antigen. On addition of a noncolored reagent the enzyme produces a color reaction where the color intensity is directly or inversely proportional to the concentration of the analyte in the sample.</p></list-item>
</list>
<p>These tests are not very sensitive, and if antigens are not pure, it can be negative in early cases. ELISA is highly sensitive for detecting antibodies, but cross-reactivity is unavoidable.<sup><xref ref-type="bibr" rid="bibr51-1534734612438549">51</xref>,<xref ref-type="bibr" rid="bibr52-1534734612438549">52</xref></sup></p>
</sec>
<sec id="section13-1534734612438549">
<title>Bone Scan, Computed Tomography Scan, and Magnetic Resonance Imaging</title>
<p>Radiological studies are gaining importance in diagnosis and planning of management. They help in accurately identifying the location of the lesion, planning of surgical management, and also monitoring of its response to treatment in the form of lesion shrinkage. They are widely available but expensive.<sup><xref ref-type="bibr" rid="bibr50-1534734612438549">50</xref></sup> In a resource limited setting, this investigation can be used for cases not identifiable by other modalities.</p>
</sec>
<sec id="section14-1534734612438549">
<title>DNA Sequencing</title>
<p>DNA sequencing identified a case of <italic>Fusarium solani</italic> infection by analysis of fungal internal transcribed spacers 1 and 2 and 5.8S ribosomal DNA regions.<sup><xref ref-type="bibr" rid="bibr21-1534734612438549">21</xref></sup> 16S ribosomal RNA gene sequencing identified an unusual Nocardia species, <italic>N veterana</italic>, by biochemical characterization for the first time.<sup><xref ref-type="bibr" rid="bibr24-1534734612438549">24</xref></sup></p>
</sec>
<sec id="section15-1534734612438549">
<title>Radiology</title>
<p>Davies reported a variety of radiological changes in Madura foot.</p>
<list id="list6-1534734612438549" list-type="simple">
<list-item><p><italic>The early change</italic>: Soft tissue granuloma, appears as a single or multiple soft tissue shadows with calcification and obliteration of the fascial planes. The cortex loses definition due to external compression by the granuloma leading to bone scalloping.</p></list-item>
<list-item><p><italic>The disease development</italic>: When the bone is involved, there may be a periosteal reaction. This will lead to the formation of sun ray appearance and Codman triangle, an appearance that may be indistinguishable from that of osteogenic sarcoma.</p></list-item>
<list-item><p><italic>The late stage</italic>: Formation of cavities that may be multiply punched out throughout an otherwise bone of normal density. These cavities are large in size, few in number, with well-defined margins in eumycetoma. The cavities in actinomycetoma are usually smaller in size, are numerous, and have no definite margins.</p></list-item>
<list-item><p><italic>The terminal stage</italic>: Gives a <italic>melting snow</italic> appearance.<sup><xref ref-type="bibr" rid="bibr53-1534734612438549">53</xref></sup> Osteogenic sarcoma and tuberculosis are differential diagnoses on radiological examination.<sup><xref ref-type="bibr" rid="bibr40-1534734612438549">40</xref></sup></p></list-item>
</list>
</sec>
</sec>
<sec id="section16-1534734612438549">
<title>X-Ray</title>
<p>Madurella mycetoma appears as localized, large, well-defined, black fungus balls.<sup><xref ref-type="bibr" rid="bibr54-1534734612438549">54</xref></sup> Plain radiographic classification is useful in monitoring treatment response. Stage 0 shows soft tissue swelling without bone involvement. Stage 1 shows the pressure effects of the expanding granuloma on normal bones. Stage 2 is when there is periosteal reaction of the bone without bone invasion. In Stage 3 there is cortical erosion and medullary invasion. Stage 4 is when infection spreads longitudinally along a single ray. Horizontal spread along a single row represents Stage 5. In Stage 6 there is multidirectional and uncontrolled spread.<sup><xref ref-type="bibr" rid="bibr32-1534734612438549">32</xref></sup></p>
<p>A study conducted in Saudi Arabia also revealed similar changes on X-rays and computed tomography (CT) scans (Somotom DR-2 machines). Magnetic resonance imaging (MRI) is useful for studying the soft tissue invasion. The method of choice for the pretherapy assessment of bone involvement is CT scan.<sup><xref ref-type="bibr" rid="bibr5-1534734612438549">5</xref></sup> The dot in circle sign is highly specific for mycetoma. The fungal grains appear as hypointense foci within high-intensity spherical lesions representing the surrounding granulomata on T2-weighted, short inversion time inversion-recovery, and T1-weighted fat-saturated gadolinium-enhanced images.<sup><xref ref-type="bibr" rid="bibr55-1534734612438549">55</xref></sup></p>
<p>Eumycotic lesions form few large cavities ≥1 cm in diameter, whereas actinomycetes form many small cavities giving a <italic>moth-eaten</italic> appearance.<sup><xref ref-type="bibr" rid="bibr56-1534734612438549">56</xref></sup></p>
<p>Osteoporosis at and distal to the affected part is sometimes observed because of disuse atrophy or external compression of the bone and its blood supply by the granuloma.</p>
</sec>
<sec id="section17-1534734612438549">
<title>Complications</title>
<sec id="section18-1534734612438549">
<title>Due to Disease</title>
<sec id="section19-1534734612438549">
<title>Secondary bacterial infections</title>
<p>In Sudan, <italic>Staphylococcus aureus, Streptococcus pyogenes</italic>, and <italic>Proteus mirabilis</italic> were common secondary invaders.<sup><xref ref-type="bibr" rid="bibr46-1534734612438549">46</xref></sup> Eumycetomas are susceptible to SBIs, contrary to popular belief that the antibiotics produced by the fungi keep it sterile.<sup><xref ref-type="bibr" rid="bibr40-1534734612438549">40</xref>,<xref ref-type="bibr" rid="bibr57-1534734612438549">57</xref></sup> The lower incidence of SBI in actinomycetomas is because these patients receive streptomycin as part of antimicrobial therapy.<sup><xref ref-type="bibr" rid="bibr46-1534734612438549">46</xref></sup></p>
</sec>
<sec id="section20-1534734612438549">
<title>Dorsolumbar actinomycetoma with spastic paraplegia</title>
<p>Three out of 130 patients in Senegal who had back injury later developed dorsolumbar actinomycetoma and neurological complications such as spastic paraplegia.<sup><xref ref-type="bibr" rid="bibr16-1534734612438549">16</xref></sup> Contiguous spread and visceral involvement occur.<sup><xref ref-type="bibr" rid="bibr43-1534734612438549">43</xref></sup></p>
</sec>
<sec id="section21-1534734612438549">
<title>Delayed presentation</title>
<p>Asymptomatic and chronic course leads to the disease presenting at an advanced stage for the first time.<sup><xref ref-type="bibr" rid="bibr8-1534734612438549">8</xref></sup></p>
</sec>
</sec>
<sec id="section22-1534734612438549">
<title>Due to Therapy</title>
<p>Toxicity may occur due to prolonged antimicrobial or antifungal therapy, anemia, or leucopenia.</p>
<p><sup><xref ref-type="bibr" rid="bibr57-1534734612438549">57</xref></sup> Drug resistance may be seen since treatment is of prolonged duration,<sup><xref ref-type="bibr" rid="bibr58-1534734612438549">58</xref></sup> especially in bone and visceral involvement and Dapsone syndrome.</p>
</sec>
<sec id="section23-1534734612438549">
<title>During Diagnosis</title>
<p>Multiple surgical biopsies are sometimes required for culture and staining to arrive at the etiological diagnosis.</p>
<p>This increases the morbidity and delays diagnosis and treatment.<sup><xref ref-type="bibr" rid="bibr56-1534734612438549">56</xref></sup></p>
</sec>
</sec>
<sec id="section24-1534734612438549">
<title>Treatment</title>
<p>The primary step is the distinction between eumycetoma and actinomycetoma.<sup><xref ref-type="bibr" rid="bibr16-1534734612438549">16</xref></sup> A tentative diagnosis based on the grain color is sufficient to commence therapy. Melanoid grains are always caused by fungi and ochroid or pale grains by actinomycetes.</p>
<sec id="section25-1534734612438549">
<title>Treatment of Actinomycetoma</title>
<p>Actinomycetoma is amenable to medical treatment with antibiotics and other chemotherapeutic agents. Chemotherapy causes radiological improvement consisting of remolding, absorption of the sclerotic bone, and reappearance of the normal trabecular pattern. Combined drug therapy is always preferred to a single drug in order to avoid drug resistance and eradicate residual infection.</p>
<p>Therapeutic end point is clinical, serological, and radiological cure. The time taken for this rarely exceeds a year. Preoperative and postoperative chemotherapy improves the prognosis.<sup><xref ref-type="bibr" rid="bibr2-1534734612438549">2</xref></sup> Dieng et al<sup><xref ref-type="bibr" rid="bibr16-1534734612438549">16</xref></sup> reported complete cure with antibiotics in 66 patients with actinomycetoma in Senegal.</p>
<list id="list7-1534734612438549" list-type="bullet">
<list-item><p>Trimethoprim–sulfamethoxazole (TMP-SMX) and diaminodiphenylsulfone (DDS; 1.5mg/kg twice daily) were an effective combination.</p></list-item></list>
<p>Failures were successfully treated with amoxicillin/clavulanate.<sup><xref ref-type="bibr" rid="bibr10-1534734612438549">10</xref></sup> Gentamycin and cefotaxime,<sup><xref ref-type="bibr" rid="bibr37-1534734612438549">37</xref></sup> amikacin, streptomycin, kanamycin, or phosphomycin may be added.<sup><xref ref-type="bibr" rid="bibr59-1534734612438549">59</xref></sup></p>
<list id="list8-1534734612438549" list-type="bullet">
<list-item><p><italic>Nocardia brasiliensis</italic> infection in a 10-year-old responded to TMP-SMX with DDS and rifampicin.<sup><xref ref-type="bibr" rid="bibr60-1534734612438549">60</xref></sup></p></list-item></list>
<p>We add a word of caution: The patient who requires dapsone should be tested for glucose-6-phosphate dehydrogenase deficiency before commencing therapy.</p>
<p>The Welsh regimen, which proposed the use of amikacin with TMP-SMX in the treatment of actinomycetoma, was first published by Welsh et al<sup><xref ref-type="bibr" rid="bibr61-1534734612438549">61</xref></sup> in 1987. In 2011, Palit et al<sup><xref ref-type="bibr" rid="bibr43-1534734612438549">43</xref></sup> reported a dramatic response of mycetoma to the modified 2-step regimen. An intensive phase follows, with intravenous gentamicin 80 mg 12th hourly and cotrimoxazole 320/1600 mg twice daily orally for 4weeks. A maintenance phase is next, with oral cotrimoxazole and doxycycline 100 mg twice daily</p>
<p>Addition of rifampicin to the Welsh regimen showed no recurrences for up to 18 months.<sup><xref ref-type="bibr" rid="bibr62-1534734612438549">62</xref></sup> If resistant, streptomycin can be used.<sup><xref ref-type="bibr" rid="bibr63-1534734612438549">63</xref></sup></p>
<p>Streptomyces species were responsive to novobiocin, gentamycin, and doxycycline.</p>
<p>Fusidic acid, bacitracin, streptomycin, cephaloridine, clindamycin, ampicillin, rifampicin, and tetracycline were less effective. Resistance to amphotericin B, penicillin, and sulphamethoxazole was noted.<sup><xref ref-type="bibr" rid="bibr64-1534734612438549">64</xref></sup></p>
<p>In advanced bone or visceral involvement, with streptomycin sulphate (14mg/kg/d), dapsone, TMP-SMX, sulfadoxine-pyrimethamine, rifampicin, and imipenem, were effective.<sup><xref ref-type="bibr" rid="bibr59-1534734612438549">59</xref></sup></p>
<p>In infections secondary to <italic>N brasiliensis</italic>, amoxicillin–clavulanic acid (500 mg–125 mg) is beneficial in preventing relapses.<sup><xref ref-type="bibr" rid="bibr58-1534734612438549">58</xref>,<xref ref-type="bibr" rid="bibr65-1534734612438549">65</xref></sup></p>
<p>The unusual <italic>N veterana</italic> responded to the combination of intravenous imipenem/cilastatin and amikacin along with oral clarithromycin and minocycline.<sup><xref ref-type="bibr" rid="bibr24-1534734612438549">24</xref></sup></p>
<p>The prolonged duration of treatment, a major drawback, was shortened by a 2-step regimen initiated by Ramam et al to hasten improvement and promote compliance.</p>
<list id="list9-1534734612438549" list-type="bullet">
<list-item><p>Intensive phase: Penicillin + gentamycin + co-trimoxazole (5-7 weeks), followed by amoxicillin + cotrimoxazole (2-5 months)</p></list-item>
</list>
</sec>
<sec id="section26-1534734612438549">
<title>Treatment of Eumycetoma</title>
<p>Eumycetoma can be treated with the following</p>
<list id="list10-1534734612438549" list-type="simple">
<list-item><p>Ketoconazole: 400-800 mg daily</p></list-item>
<list-item><p>Itraconazole: 400 mg itraconazole daily. P. boydii (S. apiospermum) responded</p></list-item>
<list-item><p>Good response has been noted with Terbinafine</p></list-item>
<list-item><p>Eumycetoma treatment usually extends into many years. They are well circumscribed<sup><xref ref-type="bibr" rid="bibr8-1534734612438549">8</xref>,<xref ref-type="bibr" rid="bibr17-1534734612438549">17</xref></sup> and combined medical and surgical treatment is the gold standard for management.<sup><xref ref-type="bibr" rid="bibr66-1534734612438549">66</xref></sup></p></list-item>
</list>
</sec></sec>
<sec id="section27-1534734612438549">
<title>Madurella mycetomatis</title>
<p><italic>Madurella mycetomatis</italic> has responded to</p>
<list id="list11-1534734612438549" list-type="bullet">
<list-item><p>Surgery after therapy with griseofulvin and penicillin.<sup><xref ref-type="bibr" rid="bibr57-1534734612438549">57</xref></sup></p></list-item>
<list-item><p>Oral itraconazole 400 mg daily for 3 months; followed by 200 mg daily for 9 months (the dose reduction slowed down the healing), leading to lesion encapsulation, thus making surgical removal easy. Recurrences have been noted.<sup><xref ref-type="bibr" rid="bibr10-1534734612438549">10</xref>,<xref ref-type="bibr" rid="bibr48-1534734612438549">48</xref></sup></p></list-item>
<list-item><p>Ketoconazole</p></list-item>
<list-item><p>Amphotericin B</p></list-item>
<list-item><p>Tea tree oil but not Artemesinin derivatives; has been found to penetrate the skin and help treat this fungal infection.<sup><xref ref-type="bibr" rid="bibr67-1534734612438549">67</xref></sup></p></list-item>
</list>
<p>Echinocandins: caspofungin, anidulafungin, and micafungin were unsuccessful in treating it.<sup><xref ref-type="bibr" rid="bibr68-1534734612438549">68</xref></sup></p>
<p>Kaliswaran et al<sup><xref ref-type="bibr" rid="bibr64-1534734612438549">64</xref></sup> in 2003 treated 25 patients with mycetoma foot. The actinomycetomas received 4 different regimens.</p>
<list id="list12-1534734612438549" list-type="simple">
<list-item><p><italic>Regimen 1</italic>: Welsh regimen (TMP-SMX with Amikacin)</p></list-item>
<list-item><p><italic>Regimen 2</italic>: TMP-SMX with Inj. Streptomycin</p></list-item>
<list-item><p><italic>Regimen 3</italic>: TMP-SMX with Rifampicin</p></list-item>
<list-item><p><italic>Regimen 4</italic>: TMP-SMX monotherapy</p></list-item></list>
<p>The eumycetomas received ketoconazole (regimen-A) and itraconazole (regimen-B).</p>
<p>Therapeutic outcome in actinomycotic mycetoma was good with the Welsh regimen. In eumycetoma, complete surgical excision following antifungal therapy at an early stage gave the best results.<sup><xref ref-type="bibr" rid="bibr64-1534734612438549">64</xref></sup> Carbapenems, oxazolidinones, and triazoles have emerged as promising therapeutic options.<sup><xref ref-type="bibr" rid="bibr69-1534734612438549">69</xref></sup></p>
<p>Surgery aims at complete removal or size reduction as an adjunct to medical treatment. Local anaesthesia is contraindicated because of the disease extent. Eumycetomas are well encapsulated, and if ruptured, they lead to recurrence by invasion. Actinomycetomas are ill defined, and hence healthy tissue should always be excised with the lesion. Simple bone curettage is recommended for localized bony lesions. Flooding the wound with tincture of iodine can destroy missed grains. Wound closure may require skin grafting. If the wound is left open, postoperative wounds should be dressed with 2% iodine in glycerin to destroy any fungal elements.</p>
<p>Repeated excisions of the diseased tissue, including bone, may be carried out several times to avoid the social consequences of amputation. When surgery is inadequate, amputation becomes inevitable.</p>
</sec>
<sec id="section28-1534734612438549">
<title>Follow-up</title>
<p>Mycetomas require prolonged systemic treatment. These have a propensity for liver damage. Patient review every 8 weeks to assess liver function also helps assess prognosis. Regular follow-up also aids early detection of recurrence.</p>
<p>The disease can leave behind severe scarring and in extreme cases disability. Psychological support and occupational rehabilitation are vital in the multidisciplinary management of mycetoma.</p>
</sec>
<sec id="section29-1534734612438549">
<title>Criteria for Cure</title>
<p>Disappearance of the subcutaneous mass and healing of sinuses are the main criteria. Three consecutive negative counterimmunoelectrophoresis tests 1 month apart are required. Normal bone on radiology has to be attained. There has to be absence of hyperreflective echoes and cavities on ultrasonology. No grains should be found on fine needle aspiration cytology.</p>
</sec>
<sec id="section30-1534734612438549">
<title>Differential Diagnosis</title>
<p>Chronic bacterial osteomyelitis, chronic osteitis, tuberculosis, Buruli ulcer, other deep fungal infections such as blastomycosis or coccidiomycosis, leishmaniasis, yaws, and syphilis may be considered</p>
</sec>
<sec id="section31-1534734612438549">
<title>Prognosis</title>
<p>Subcutaneous bacterial actinomycetoma is completely amenable to antibiotic therapy, whereas fungal infections have a high rate of recurrence. The eumycetomas require surgical debriding in addition to antifungals. High incidence of SBI can cause increased pain, disability, and septicaemia. This may become fatal if untreated.<sup><xref ref-type="bibr" rid="bibr12-1534734612438549">12</xref>,<xref ref-type="bibr" rid="bibr46-1534734612438549">46</xref></sup></p>
</sec>
<sec id="section32-1534734612438549">
<title>Prevention</title>
<p>No prophylaxis or vaccine is available against this disease. Health education of susceptible population about protective footwear and other risk factors can go a long way in curbing the incidence of mycetomas. Improvement in hygienic practices and living conditions can reduce this disfiguring infection. Immunocompromised populations are susceptible, and great care has to be taken to avoid nosocomial spread.</p>
</sec>
<sec id="section33-1534734612438549">
<title>Quality of Life</title>
<p>The life quality index of mycetoma patients were studied in the Mycetoma research centre in Khartoum, Sudan, in 2008 using a Glasgow Health Status Inventory. The disease negatively affects the patients’ daily routine, profession, and social life.</p>
</sec>
<sec id="section34-1534734612438549">
<title>Conclusion</title>
<p>Mycetoma is the clinical manifestation of a chronic, exogenous bacterial or fungal infection and is often at an advanced stage when diagnosed. Its asymptomatic nature leads to the patient ignoring the progression.<sup><xref ref-type="bibr" rid="bibr38-1534734612438549">38</xref>,<xref ref-type="bibr" rid="bibr70-1534734612438549">70</xref></sup> This foot pathology has increased in prevalence in the United States and Europe because of international travel and migration.<sup><xref ref-type="bibr" rid="bibr13-1534734612438549">13</xref></sup> Morphological similarities and unusual locations and presentations pose diagnostic difficulties.<sup><xref ref-type="bibr" rid="bibr39-1534734612438549">39</xref></sup> Culture is the gold standard for diagnosis. Radiological diagnosis is not accurate,<sup><xref ref-type="bibr" rid="bibr53-1534734612438549">53</xref></sup> and hence, species identification and susceptibility testing guide therapy. ELISA is useful in community surveys.</p>
<p>SBIs are common in eumycetomas, causing pain and increasing the morbidity.<sup><xref ref-type="bibr" rid="bibr46-1534734612438549">46</xref></sup> Treatment regimens are currently based on expert opinion because no randomized controlled trials have been performed. Most patients receive 3 to 24 months of therapy to obtain an adequate response.<sup><xref ref-type="bibr" rid="bibr8-1534734612438549">8</xref></sup> Treatment response is better for actinomycetomas with chemotherapy than for eumycetomas with antifungals and surgery.<sup><xref ref-type="bibr" rid="bibr10-1534734612438549">10</xref></sup> Surgical management is recommended for excising small localized lesions and debulking of massive lesions for better response to medical treatment and of lesions that become encapsulated by medical treatment. Amputation, if done, is for very advanced lesions and is recommended as a lifesaving procedure.</p>
</sec>
</body>
<back>
<app-group>
<app id="app1-1534734612438549">
<title>Appendix</title>
<sec id="section35-1534734612438549">
<title>A Case Study of a Patient With Madura Foot</title>
<p>A 35-year-old farmer presented with multiple nodules with bloody and purulent discharge encompassing the right ankle. A diagnosis of <italic>Nocardia brazeliensis</italic> was made clinically and confirmed by culture. The Welsh regimen was commenced, and the patient was treated for 6 months. For the first 2 months, he was admitted into hospital and treated with intravenous Amikacin and with oral Cotrimoxazole twice daily. At discharge, the oozing had dried up and nodules were present. Twice-daily dosage of cotrimoxazole was continued for 4 months till complete clinical resolution. At completion of therapy, there was severe scarring but no disability.</p>
<fig id="fig6-1534734612438549" position="float">
<label>Figure A.1.</label>
<caption>
<p>Ankle at presentation</p>
</caption>
<graphic xlink:href="10.1177_1534734612438549-fig6.tif"/></fig>
<fig id="fig7-1534734612438549" position="float">
<label>Figure A.2.</label>
<caption>
<p>After 2 months of amikacin</p>
</caption>
<graphic xlink:href="10.1177_1534734612438549-fig7.tif"/></fig>
<fig id="fig8-1534734612438549" position="float">
<label>Figure A.3.</label>
<caption>
<p>Scarring at completion of therapy</p>
</caption>
<graphic xlink:href="10.1177_1534734612438549-fig8.tif"/></fig>
</sec>
</app>
</app-group>
<ack>
<p>We would like to acknowledge Dr Sandhya Sridhar, Professor, Department of Pathology, Sri Ramachandra University and Prof Sandhya Sundaram, MD, Department of Pathology, Sri Ramachandra University, for providing us with the histopathology slides.</p>
</ack>
<fn-group>
<fn fn-type="conflict">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1534734612438549">
<label>1.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Hospenthal</surname><given-names>DR</given-names></name>
</person-group>. <article-title>Agents of mycetoma</article-title>. In: <person-group person-group-type="editor">
<name><surname>Mandell</surname><given-names>GL</given-names></name>
<name><surname>Bennett</surname><given-names>JE</given-names></name>
<name><surname>Dolin</surname><given-names>R</given-names></name>
</person-group>, eds. <source>Principles and Practice of Infectious Diseases</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Churchill Livingstone Elsevier</publisher-name>; <year>2009</year>: <fpage>3281</fpage>-<lpage>3286</lpage>.</citation>
</ref>
<ref id="bibr2-1534734612438549">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cathrine</surname><given-names>AN</given-names></name>
<name><surname>Bhattacharya</surname><given-names>K</given-names></name>
<name><surname>Srinivasan</surname><given-names>V</given-names></name>
</person-group>. <article-title>Mycetoma leg: a case report</article-title>. <source>Int J Low Extrem Wounds</source>. <year>2003</year>;<volume>2</volume>:<fpage>171</fpage>-<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr3-1534734612438549">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mansilla-Lory</surname><given-names>J</given-names></name>
<name><surname>Contreras-López</surname><given-names>E</given-names></name>
</person-group>. <article-title>Mycetoma in prehispanic Mexico. Review in the skeletical collection of Tlatilco culture [in Spanish]</article-title>. <source>Rev Med Inst Mex Seguro Soc</source>. <year>2009</year>;<volume>47</volume>:<fpage>237</fpage>-<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr4-1534734612438549">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lichon</surname><given-names>V</given-names></name>
<name><surname>Khachemoune</surname><given-names>A</given-names></name>
</person-group>. <article-title>Mycetoma: a review</article-title>. <source>Am J Clin Dermatol</source>. <year>2006</year>;<volume>7</volume>:<fpage>315</fpage>-<lpage>321</lpage>.</citation>
</ref>
<ref id="bibr5-1534734612438549">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Al-Ali</surname><given-names>AA</given-names></name>
<name><surname>Kashgari</surname><given-names>TQ</given-names></name>
<name><surname>Nathani</surname><given-names>PG</given-names></name>
<name><surname>Moawad</surname><given-names>MK</given-names></name>
</person-group>, <article-title>Radiological manifestations of Madura foot in the eastern province of Saudi Arabia</article-title>. <source>Ann Saudi Med</source>. <year>1997</year>;<volume>17</volume>:<fpage>298</fpage>-<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr6-1534734612438549">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bakshi</surname><given-names>R</given-names></name>
<name><surname>Mathur</surname><given-names>DR</given-names></name>
</person-group>. <article-title>Incidence and changing pattern of mycetoma in western Rajasthan</article-title>. <source>Indian J Pathol Microbiol</source>. <year>2008</year>;<volume>51</volume>:<fpage>154</fpage>-<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr7-1534734612438549">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mahgoub</surname><given-names>ES</given-names></name>
</person-group>. <article-title>Mycetomas caused by <italic>Curvularia lunata, Madurella grisea, Aspergillus nidulans</italic>, and <italic>Nocardia brasiliensis</italic> in Sudan</article-title>. <source>Sabouraudia</source>. <year>1973</year>;<volume>11</volume>:<fpage>179</fpage>-<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr8-1534734612438549">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alam</surname><given-names>K</given-names></name>
<name><surname>Maheshwari</surname><given-names>V</given-names></name>
<name><surname>Bhargava</surname><given-names>S</given-names></name>
<name><surname>Jain</surname><given-names>A</given-names></name>
<name><surname>Fatima</surname><given-names>U</given-names></name>
<name><surname>Haq</surname><given-names>EU</given-names></name>
</person-group>. <article-title>Histological diagnosis of Madura foot (mycetoma): a must for definitive treatment</article-title>. <source>J Glob Infect Dis</source>. <year>2009</year>;<volume>1</volume>: <fpage>64</fpage>-<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr9-1534734612438549">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>El Muttardi</surname><given-names>N</given-names></name>
<name><surname>Kulendren</surname><given-names>D</given-names></name>
<name><surname>Jemec</surname><given-names>B</given-names></name>
</person-group>. <article-title>Madura foot-mind the soil</article-title>. <source>J Plast Reconstr Aesthet Surg</source>. <year>2010</year>;<volume>63</volume>:<fpage>e576</fpage>-<lpage>e578</lpage>.</citation>
</ref>
<ref id="bibr10-1534734612438549">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonifaz</surname><given-names>A</given-names></name>
<name><surname>Ibarra</surname><given-names>G</given-names></name>
<name><surname>Saúl</surname><given-names>A</given-names></name>
<name><surname>Paredes-Solis</surname><given-names>V</given-names></name>
<name><surname>Carrasco-Gerard</surname><given-names>E</given-names></name>
<name><surname>Fierro-Arias</surname><given-names>L</given-names></name>
</person-group>. <article-title>Mycetoma in children: experience with 15 cases</article-title>. <source>Pediatr Infect Dis J</source>. <year>2007</year>;<volume>26</volume>:<fpage>50</fpage>-<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr11-1534734612438549">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mathur</surname><given-names>D</given-names></name>
<name><surname>Joshi</surname><given-names>K</given-names></name>
<name><surname>Mathur</surname><given-names>A</given-names></name>
</person-group>. <article-title>An etiological and pathological study of mycetoma in western Rajasthan</article-title>. <source>Curr Med Pract</source>. <year>1979</year>;<volume>23</volume>:<fpage>151</fpage>-<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr12-1534734612438549">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bedi</surname><given-names>T</given-names></name>
<name><surname>Kaur</surname><given-names>S</given-names></name>
<name><surname>Kumar</surname><given-names>B</given-names></name>
</person-group>. <article-title>Red grain mycetoma of the scalp (<italic>Actinomadura pelletieri</italic>). A case report from India</article-title>. <source>Mycopathologia</source>. <year>1978</year>;<volume>63</volume>:<fpage>127</fpage>-<lpage>128</lpage>.</citation>
</ref>
<ref id="bibr13-1534734612438549">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malone</surname><given-names>M</given-names></name>
<name><surname>Gannass</surname><given-names>A</given-names></name>
<name><surname>Bowling</surname><given-names>F</given-names></name>
</person-group>. <article-title>A chronic, destructive mycetoma infection in a diabetic foot in Saudi Arabia</article-title>. <source>Int J Low Extrem Wounds</source>. <year>2011</year>;<volume>10</volume>:<fpage>12</fpage>-<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr14-1534734612438549">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tight</surname><given-names>RR</given-names></name>
<name><surname>Bartlett</surname><given-names>MS</given-names></name>
</person-group>. <article-title>Actinomycetoma in the United States</article-title>. <source>Clin Infect Dis</source>. <year>1981</year>;<volume>3</volume>:<fpage>1139</fpage>-<lpage>1150</lpage>.</citation>
</ref>
<ref id="bibr15-1534734612438549">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Venugopal</surname><given-names>PL</given-names></name>
<name><surname>Venugopal</surname><given-names>TL</given-names></name>
</person-group>. <article-title><italic>Actinomadura madurae</italic> causing mycetoma in Madras</article-title>. <source>Indian J Pathol Microbiol</source>. <year>1991</year>;<volume>34</volume>:<fpage>119</fpage>-<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr16-1534734612438549">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dieng</surname><given-names>M</given-names></name>
<name><surname>Sy</surname><given-names>M</given-names></name>
<name><surname>Diop</surname><given-names>B</given-names></name>
<name><surname>Niang</surname><given-names>S</given-names></name>
<name><surname>Ndiaye</surname><given-names>B</given-names></name>
</person-group>. <article-title>Mycetoma: 130 cases</article-title>. <source>Ann Dermatol Venereol</source>. <year>2003</year>;<volume>130</volume>(<issue>1 pt 1</issue>):<fpage>16</fpage>-<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr17-1534734612438549">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Palestine</surname><given-names>RF</given-names></name>
<name><surname>Rogers</surname><given-names>RS</given-names><suffix>III</suffix></name>
</person-group>. <article-title>Diagnosis and treatment of mycetoma</article-title>. <source>J Am Acad Dermatol</source>. <year>1982</year>;<volume>6</volume>:<fpage>107</fpage>-<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr18-1534734612438549">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gumaa</surname><given-names>S</given-names></name>
</person-group>. <article-title>The aetiology and epidemiology of mycetoma</article-title>. <source>Sudan Med J</source>. <year>1994</year>;<volume>32</volume>(<issue>suppl 1</issue>):<fpage>14</fpage>-<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr19-1534734612438549">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Padhi</surname><given-names>S</given-names></name>
<name><surname>Uppin</surname><given-names>SG</given-names></name>
<name><surname>Uppin</surname><given-names>MS</given-names></name><etal/>
</person-group>. <article-title>Mycetoma in south India: retrospective analysis of 13 cases and description of two cases caused by unusual pathogens: <italic>Neoscytalidium dimidiatum</italic> and <italic>Aspergillus flavus</italic></article-title>. <source>Int J Dermatol</source>. <year>2010</year>;<volume>49</volume>:<fpage>1289</fpage>-<lpage>1296</lpage>.</citation>
</ref>
<ref id="bibr20-1534734612438549">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zoutman</surname><given-names>D</given-names></name>
<name><surname>Sigler</surname><given-names>L</given-names></name>
</person-group>. <article-title>Mycetoma of the foot caused by <italic>Cylindrocarpon destructans</italic></article-title>. <source>J Clin Microbiol</source>. <year>1991</year>;<volume>29</volume>:<fpage>1855</fpage>-<lpage>1859</lpage>.</citation>
</ref>
<ref id="bibr21-1534734612438549">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yera</surname><given-names>H</given-names></name>
<name><surname>Bougnoux</surname><given-names>M</given-names></name>
<name><surname>Jeanrot</surname><given-names>C</given-names></name>
<name><surname>Baixench</surname><given-names>M</given-names></name>
<name><surname>De Pinieux</surname><given-names>G</given-names></name>
<name><surname>Dupouy-Camet</surname><given-names>J</given-names></name>
</person-group>. <article-title>Mycetoma of the foot caused by <italic>Fusarium solani</italic>: identification of the etiologic agent by DNA sequencing</article-title>. <source>J Clin Microbiol</source>. <year>2003</year>;<volume>41</volume>:<fpage>1805</fpage>-<lpage>1808</lpage>.</citation>
</ref>
<ref id="bibr22-1534734612438549">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pilsczek</surname><given-names>FH</given-names></name>
<name><surname>Augenbraun</surname><given-names>M</given-names></name>
</person-group>. <article-title>Mycetoma fungal infection: multiple organisms as colonizers or pathogens</article-title>. <source>Rev Soc Bras Med Trop</source>. <year>2004</year>;<volume>40</volume>:<fpage>463</fpage>-<lpage>465</lpage>.</citation>
</ref>
<ref id="bibr23-1534734612438549">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taralakshmi</surname><given-names>V</given-names></name>
<name><surname>Pankajalakshmi</surname><given-names>V</given-names></name>
<name><surname>Arumugam</surname><given-names>S</given-names></name>
<name><surname>Subramanian</surname><given-names>S</given-names></name>
</person-group>. <article-title>Mycetoma caused by <italic>Madurella mycetomii</italic> in Madras</article-title>. <source>Australas J Dermatol</source>. <year>1978</year>;<volume>19</volume>:<fpage>125</fpage>-<lpage>129</lpage>.</citation>
</ref>
<ref id="bibr24-1534734612438549">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kashima</surname><given-names>M</given-names></name>
<name><surname>Kano</surname><given-names>R</given-names></name>
<name><surname>Mikami</surname><given-names>Y</given-names></name><etal/>
</person-group>. <article-title>A successfully treated case of mycetoma due to <italic>Nocardia veterana</italic></article-title>. <source>Br J Dermatol</source>. <year>2005</year>;<volume>152</volume>:<fpage>1349</fpage>-<lpage>1352</lpage>.</citation>
</ref>
<ref id="bibr25-1534734612438549">
<label>25.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Rook</surname><given-names>A</given-names></name>
<name><surname>Burns</surname><given-names>T</given-names></name>
</person-group>. <source>Rook’s Textbook of Dermatology</source>. <volume>Vol 4</volume>. <publisher-loc>Malden, MA</publisher-loc>: <publisher-name>Blackwell</publisher-name>; <year>2010</year>.</citation>
</ref>
<ref id="bibr26-1534734612438549">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van</surname><given-names>de</given-names></name>
<name><surname>Sande</surname><given-names>WW</given-names></name>
<name><surname>Fahal</surname><given-names>A</given-names></name>
<name><surname>Verbrugh</surname><given-names>H</given-names></name>
<name><surname>van Belkum</surname><given-names>A</given-names></name>
</person-group>. <article-title>Polymorphisms in genes involved in innate immunity predispose toward mycetoma susceptibility</article-title>. <source>J Immunol</source>. <year>2007</year>;<volume>179</volume>:<fpage>3065</fpage>-<lpage>3074</lpage>.</citation>
</ref>
<ref id="bibr27-1534734612438549">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hernández-Hernández</surname><given-names>F</given-names></name>
<name><surname>Lopex-Martinez</surname><given-names>R</given-names></name>
<name><surname>Méndez-Tovar</surname><given-names>LJ</given-names></name>
<name><surname>Manzano-Gayosso</surname><given-names>P</given-names></name>
</person-group>. <article-title><italic>Nocardia brasiliensis</italic>: in vitro and in vivo growth in response to steroid sex hormones</article-title>. <source>Mycopathologia</source>. <year>1995</year>;<volume>132</volume>:<fpage>79</fpage>-<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr28-1534734612438549">
<label>28.</label>
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Bashir</surname><given-names>A</given-names></name>
<name><surname>Saaed</surname><given-names>AM</given-names></name>
<name><surname>Frede</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Role of hypoxia-inducible factor-1 in the induction of angiogenesis in mycetoma lesion</article-title>. <conf-name>Paper presented at: Mycetoma International Week</conf-name>; <conf-date>January 2009</conf-date>; <conf-loc>Khartoum, Sudan</conf-loc>.</citation>
</ref>
<ref id="bibr29-1534734612438549">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klokke</surname><given-names>A</given-names></name>
<name><surname>Swamidasan</surname><given-names>G</given-names></name>
<name><surname>Anguli</surname><given-names>R</given-names></name>
<name><surname>Verghese</surname><given-names>A</given-names></name>
</person-group>. <article-title>The causal agents of mycetoma in south India</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>1968</year>;<volume>62</volume>:<fpage>509</fpage>-<lpage>514</lpage>.</citation>
</ref>
<ref id="bibr30-1534734612438549">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abbott</surname><given-names>P</given-names></name>
</person-group>. <article-title>Mycetoma in the Sudan</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>1956</year>;<volume>50</volume>:<fpage>11</fpage>-<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr31-1534734612438549">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Magana</surname><given-names>M</given-names></name>
</person-group>. <article-title>Mycetoma</article-title>. <source>Int J Dermatol</source>. <year>1984</year>;<volume>23</volume>:<fpage>221</fpage>-<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr32-1534734612438549">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharif</surname><given-names>H</given-names></name>
<name><surname>Clark</surname><given-names>D</given-names></name>
<name><surname>Aabed</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Mycetoma: comparison of MR imaging with CT</article-title>. <source>Radiology</source>. <year>1991</year>;<volume>178</volume>:<fpage>865</fpage>-<lpage>870</lpage>.</citation>
</ref>
<ref id="bibr33-1534734612438549">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>JD SP</given-names></name>
<name><surname>McGarry</surname><given-names>JJ</given-names></name>
</person-group>. <article-title>Recurrent mycetoma of the foot</article-title>. <source>J Foot Ankle Surg</source>. <year>1999</year>;<volume>38</volume>:<fpage>55</fpage>-<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr34-1534734612438549">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mercut</surname><given-names>D</given-names></name>
<name><surname>Tita</surname><given-names>C</given-names></name>
<name><surname>Ianosi</surname><given-names>G</given-names></name>
<name><surname>Ianosi</surname><given-names>S</given-names></name>
<name><surname>Tita</surname><given-names>M</given-names></name>
</person-group>. <article-title>Madura’s foot (mycetoma)</article-title>. <source>Chirurgia</source>. <year>2003</year>;<volume>98</volume>:<fpage>261</fpage>-<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr35-1534734612438549">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zaios</surname><given-names>N</given-names></name>
<name><surname>Teplin</surname><given-names>D</given-names></name>
<name><surname>Rebel</surname><given-names>G</given-names></name>
</person-group>. <article-title>Mycetoma</article-title>. <source>Arch Dermatol</source>. <year>1969</year>;<volume>99</volume>:<fpage>215</fpage>-<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr36-1534734612438549">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meis</surname><given-names>J</given-names></name>
<name><surname>Schouten</surname><given-names>R</given-names></name>
<name><surname>Verweij</surname><given-names>P</given-names></name>
<name><surname>Dolmans</surname><given-names>W</given-names></name>
<name><surname>Wetzels</surname><given-names>J</given-names></name>
</person-group>. <article-title>Atypical presentation of <italic>Madurella mycetomatis</italic> mycetoma in a renal transplant patient</article-title>. <source>Transpl Infect Dis</source>. <year>2000</year>;<volume>2</volume>:<fpage>96</fpage>-<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr37-1534734612438549">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>N</given-names></name>
<name><surname>Mendiratta</surname><given-names>V</given-names></name>
<name><surname>Sharma</surname><given-names>RC</given-names></name>
<name><surname>Hemal</surname><given-names>U</given-names></name>
<name><surname>Verma</surname><given-names>M</given-names></name>
</person-group>. <article-title>Pulse therapy with amikacin and dapsone for the treatment of actinomycotic foot: a case report</article-title>. <source>J Dermatol</source>. <year>2003</year> <volume>30</volume>:<fpage>742</fpage>-<lpage>747</lpage>.</citation>
</ref>
<ref id="bibr38-1534734612438549">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fahal</surname><given-names>A</given-names></name>
<name><surname>Sharfi</surname><given-names>A</given-names></name>
<name><surname>Sheik</surname><given-names>H</given-names></name>
<name><surname>El Hassan</surname><given-names>A</given-names></name>
<name><surname>Mahgoub</surname><given-names>E</given-names></name>
</person-group>. <article-title>Internal fistula formation: an unusual complication of mycetoma</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>1996</year>;<volume>90</volume>:<fpage>550</fpage>-<lpage>552</lpage>.</citation>
</ref>
<ref id="bibr39-1534734612438549">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Diallo</surname><given-names>M</given-names></name>
<name><surname>Niang</surname><given-names>S</given-names></name>
<name><surname>Tounkara</surname><given-names>T</given-names></name>
<name><surname>Fricker</surname><given-names>A</given-names></name>
<name><surname>Mbaye</surname><given-names>P</given-names></name>
</person-group>. <article-title>Unusual presentation of mycetoma caused by <italic>Actinomadurella pelletieri</italic> on the scalp</article-title>. <source>Med Trop</source>. <year>2011</year>;<volume>71</volume>:<fpage>179</fpage>-<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr40-1534734612438549">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fahal</surname><given-names>A</given-names></name>
<name><surname>Hassan</surname><given-names>M</given-names></name>
</person-group>. <article-title>Mycetoma</article-title>. <source>B J Surg</source>. <year>1992</year>;<volume>79</volume>:<fpage>1138</fpage>-<lpage>1141</lpage>.</citation>
</ref>
<ref id="bibr41-1534734612438549">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>S</given-names></name>
<name><surname>Jain</surname><given-names>K</given-names></name>
<name><surname>Parmar</surname><given-names>C</given-names></name>
<name><surname>Shah</surname><given-names>P</given-names></name>
<name><surname>Raval</surname><given-names>RC</given-names></name>
</person-group>. <article-title>Mycetoma: nonvenereal perineal lesions</article-title>. <source>Indian J Sex Transm Dis</source>. <year>2010</year>;<volume>31</volume>:<fpage>39</fpage>-<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr42-1534734612438549">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Samaila</surname><given-names>MO</given-names></name>
<name><surname>Abdullahi</surname><given-names>K</given-names></name>
</person-group>. <article-title>Cutaneous manifestations of deep mycosis: an experience in a tropical pathology laboratory</article-title>. <source>Indian J Dermatol</source>. <year>2011</year>;<volume>56</volume>:<fpage>282</fpage>-<lpage>286</lpage>.</citation>
</ref>
<ref id="bibr43-1534734612438549">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Palit</surname><given-names>A</given-names></name>
<name><surname>Ragunatha</surname><given-names>S</given-names></name>
<name><surname>Inamadar</surname><given-names>AC</given-names></name>
</person-group>. <article-title>Actinomycetoma: dramatic response to modified two step regimen</article-title>. <source>Int J Dermatol</source>. <year>2011</year>;<volume>50</volume>:<fpage>446</fpage>-<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr44-1534734612438549">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tilak</surname><given-names>R</given-names></name>
<name><surname>Singh</surname><given-names>S</given-names></name>
<name><surname>Garg</surname><given-names>A</given-names></name>
<name><surname>Bassi</surname><given-names>J</given-names></name>
<name><surname>Tilak</surname><given-names>V</given-names></name>
<name><surname>Gulati</surname><given-names>AK</given-names></name>
</person-group>. <article-title>A case of Actinomycotic mycetoma involving the right foot</article-title>. <source>J Infec Dev Ctries</source>. <year>2009</year>;<volume>3</volume>:<fpage>71</fpage>-<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr45-1534734612438549">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hemalata</surname><given-names>M</given-names></name>
<name><surname>Prasad</surname><given-names>S</given-names></name>
<name><surname>Venkatesh</surname><given-names>K</given-names></name>
<name><surname>Niveditha</surname><given-names>SR</given-names></name>
<name><surname>Kumar</surname><given-names>SA</given-names></name>
</person-group>. <article-title>Cytological diagnosis of actinomycosis and eumycetoma: a report of two cases</article-title>. <source>Diagn Cytopathol</source>. <year>2010</year>;<volume>38</volume>: <fpage>918</fpage>-<lpage>920</lpage>.</citation>
</ref>
<ref id="bibr46-1534734612438549">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>AO</given-names></name>
<name><surname>Abugroun</surname><given-names>ES</given-names></name>
</person-group>. <article-title>Unexpected high prevalence of secondary bacterial infection in patients with mycetoma</article-title>. <source>J Clin Microbiol</source>. <year>1998</year>;<volume>36</volume>:<fpage>850</fpage>-<lpage>851</lpage>.</citation>
</ref>
<ref id="bibr47-1534734612438549">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barnetson</surname><given-names>R ML</given-names></name>
</person-group>. <article-title>Mycetoma (review)</article-title>. <source>Br J Dermatol</source>. <year>1978</year>;<volume>99</volume>:<fpage>227</fpage>-<lpage>230</lpage>.</citation>
</ref>
<ref id="bibr48-1534734612438549">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fahal</surname><given-names>AH</given-names></name>
<name><surname>Rahman</surname><given-names>I</given-names></name>
<name><surname>El-Hassan</surname><given-names>A</given-names></name>
<name><surname>Rahman</surname><given-names>M</given-names></name>
<name><surname>Zijlstra</surname><given-names>E</given-names></name>
</person-group>. <article-title>The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to <italic>Madurella mycetomatis</italic></article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>2011</year>;<volume>105</volume>:<fpage>127</fpage>-<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr49-1534734612438549">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van</surname><given-names>de</given-names></name>
<name><surname>Sande</surname><given-names>WW</given-names></name>
<name><surname>de Kat</surname><given-names>J</given-names></name>
<name><surname>Coppens</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Melanin biosynthesis in <italic>Madurella mycetomatis</italic> and its effect on susceptibility to itraconazole and ketoconazole</article-title>. <source>Microbes Infect</source>. <year>2007</year>;<volume>9</volume>:<fpage>1114</fpage>-<lpage>1123</lpage>.</citation>
</ref>
<ref id="bibr50-1534734612438549">
<label>50.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Fahal</surname><given-names>AH</given-names></name>
</person-group>. <article-title>Evidence based guidelines for the management of mycetoma patients</article-title>. <comment><ext-link ext-link-type="uri" xlink:href="http://mycetoma.uofk.edu/academic/updates_MMG.htm">http://mycetoma.uofk.edu/academic/updates_MMG.htm</ext-link></comment>. <access-date>Accessed January 25, 2012</access-date>.</citation>
</ref>
<ref id="bibr51-1534734612438549">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McLaren</surname><given-names>ML</given-names></name>
<name><surname>Mahgoub</surname><given-names>ES</given-names></name>
<name><surname>Georgakopoulos</surname><given-names>E</given-names></name>
</person-group>. <article-title>Preliminary investigation on the use of the enzyme linked immunosorbent assay (ELISA) in the serodiagnosis of mycetoma</article-title>. <source>Sabouraudia</source>. <year>1978</year>;<volume>16</volume>:<fpage>225</fpage>-<lpage>228</lpage>.</citation>
</ref>
<ref id="bibr52-1534734612438549">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salinas-Carmona</surname><given-names>MC</given-names></name>
<name><surname>Welsh</surname><given-names>O</given-names></name>
<name><surname>Casillas</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Enzyme-linked immunosorbent assay for serological diagnosis of <italic>Nocardia brasiliensis</italic> and clinical correlation with mycetoma infections</article-title>. <source>J Clin Microbiol</source>. <year>1993</year>;<volume>31</volume>:<fpage>2901</fpage>-<lpage>2906</lpage>.</citation>
</ref>
<ref id="bibr53-1534734612438549">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davies</surname><given-names>A</given-names></name>
</person-group>. <article-title>The bone changes of Madura foot</article-title>. <source>Radiology</source>. <year>1958</year>;<volume>70</volume>(<issue>6</issue>):<fpage>841</fpage>-<lpage>847</lpage>.</citation>
</ref>
<ref id="bibr54-1534734612438549">
<label>54.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Sutton</surname><given-names>D</given-names></name>
</person-group>. <article-title>Bone and joint infections, mycetoma</article-title>. In: <source>A Textbook of Radiology and Imaging</source>. <edition>3rd ed.</edition> <publisher-loc>London, England</publisher-loc>: <publisher-name>Churchill Livingstone</publisher-name>; <year>1980</year>:<fpage>52</fpage>-<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr55-1534734612438549">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sarris</surname><given-names>I</given-names></name>
<name><surname>Berendt</surname><given-names>A</given-names></name>
<name><surname>Athanasous</surname><given-names>N</given-names></name>
<name><surname>Ostlere</surname><given-names>S</given-names></name>
</person-group>. <article-title>MRI of mycetoma of the foot: two cases demonstrating the dot-in-circle sign</article-title>. <source>Skeletal Radiol</source>. <year>2003</year>;<volume>32</volume>:<fpage>179</fpage>-<lpage>183</lpage>.</citation>
</ref>
<ref id="bibr56-1534734612438549">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lewall</surname><given-names>D</given-names></name>
<name><surname>Ofole</surname><given-names>S</given-names></name>
<name><surname>Bendl</surname><given-names>B</given-names></name>
</person-group>. <article-title>Mycetoma</article-title>. <source>Skeletal Radiol</source>. <year>1985</year>;<volume>14</volume>(<issue>4</issue>):<fpage>257</fpage>-<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr57-1534734612438549">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mahgoub</surname><given-names>E</given-names></name>
</person-group>. <article-title>Medical management of mycetoma</article-title>. <source>Bull World Health Organ</source>. <year>1976</year>;<volume>54</volume>:<fpage>303</fpage>-<lpage>310</lpage>.</citation>
</ref>
<ref id="bibr58-1534734612438549">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gomez</surname><given-names>A</given-names></name>
<name><surname>Saul</surname><given-names>A</given-names></name>
<name><surname>Bonieaz</surname><given-names>A</given-names></name>
<name><surname>Lopez</surname><given-names>M</given-names></name>
</person-group>. <article-title>Amoxicillin and clavulanic acid in the treatment of actinomycetoma</article-title>. <source>Int J Dermatol</source>. <year>1993</year>;<volume>32</volume>:<fpage>218</fpage>-<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr59-1534734612438549">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fuentes</surname><given-names>A</given-names></name>
<name><surname>Arenas</surname><given-names>R</given-names></name>
<name><surname>Reyes</surname><given-names>M</given-names></name>
<name><surname>Fernández</surname><given-names>R</given-names></name>
<name><surname>Zacarías</surname><given-names>R</given-names></name>
</person-group>. <article-title>Actinomycetoma and Nocardia sp. report of five cases treated with imipenem or imipenem plus amikacin</article-title>. <source>Gac Med Mex</source>. <year>2006</year>;<volume>142</volume>:<fpage>247</fpage>-<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr60-1534734612438549">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pulikot</surname><given-names>A</given-names></name>
</person-group>. <article-title>Mycetoma of the sole</article-title>. <source>Ann Trop Paediatr</source>. <year>2002</year>;<volume>22</volume>:<fpage>187</fpage>-<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr61-1534734612438549">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Welsh</surname><given-names>O</given-names></name>
<name><surname>Sauceda</surname><given-names>E</given-names></name>
<name><surname>Gonzalez</surname><given-names>J</given-names></name>
<name><surname>Ocampo</surname><given-names>J</given-names></name>
</person-group>. <article-title>Amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of actinomycotic mycetoma</article-title>. <source>J Am Acad Dermatol</source>. <year>1987</year>;<volume>17</volume>:<fpage>443</fpage>-<lpage>448</lpage>.</citation>
</ref>
<ref id="bibr62-1534734612438549">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Damle</surname><given-names>D</given-names></name>
<name><surname>Mahajan</surname><given-names>P</given-names></name>
<name><surname>Pradhan</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Modified Welsh regimen: a promising therapy for actinomycetoma</article-title>. <source>J Drugs Dermatol</source>. <year>2008</year>;<volume>7</volume>:<fpage>853</fpage>-<lpage>856</lpage>.</citation>
</ref>
<ref id="bibr63-1534734612438549">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>A</given-names></name>
<name><surname>van</surname><given-names>de</given-names></name>
<name><surname>Sande</surname><given-names>WW</given-names></name>
<name><surname>Fahal</surname><given-names>A</given-names></name>
<name><surname>Bakker-Woudenberg</surname><given-names>I</given-names></name>
<name><surname>Verbrugh</surname><given-names>H</given-names></name>
<name><surname>van Belkum</surname><given-names>A</given-names></name>
</person-group>. <article-title>Management of mycetoma: major challenge in tropical mycoses with limited international recognition</article-title>. <source>Curr Opin Infect Dis</source>. <year>2007</year>;<volume>20</volume>:<fpage>146</fpage>-<lpage>151</lpage>.</citation>
</ref>
<ref id="bibr64-1534734612438549">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaliswaran</surname><given-names>A</given-names></name>
<name><surname>Sentamilselvi</surname><given-names>G</given-names></name>
<name><surname>Janaki</surname><given-names>C</given-names></name>
<name><surname>Janaki</surname><given-names>V</given-names></name>
</person-group>. <article-title>Therapeutic response in mycetoma: a study of different regimens</article-title>. <source>Indian J Dermatol</source>. <year>2003</year>;<volume>48</volume>:<fpage>154</fpage>-<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr65-1534734612438549">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ameen</surname><given-names>M</given-names></name>
<name><surname>Arenas</surname><given-names>R</given-names></name>
<name><surname>Vásquez del Mercado</surname><given-names>E</given-names></name>
<name><surname>Fernández</surname><given-names>R</given-names></name>
<name><surname>Torres</surname><given-names>E</given-names></name>
<name><surname>Zacarias</surname><given-names>R</given-names></name>
</person-group>. <article-title>Efficacy of imipenem therapy for <italic>Nocardia actinomycetomas</italic> refractory to sulfonamides</article-title>. <source>J Am Acad Dermatol</source>. <year>2010</year>;<volume>62</volume>:<fpage>239</fpage>-<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr66-1534734612438549">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fahal</surname><given-names>AH</given-names></name>
</person-group>. <article-title>Management of mycetoma</article-title>. <source>Expert Rev Dermatol</source>. <year>2010</year>;<volume>5</volume>:<fpage>87</fpage>-<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr67-1534734612438549">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van</surname><given-names>de</given-names></name>
<name><surname>Sande</surname><given-names>WW</given-names></name>
<name><surname>Fahal</surname><given-names>AH</given-names></name>
<name><surname>Riley</surname><given-names>TV</given-names></name>
<name><surname>Verbrugh</surname><given-names>H</given-names></name>
<name><surname>van Belkum</surname><given-names>A</given-names></name>
</person-group>. <article-title>In vitro susceptibility of <italic>Madurella mycetomatis</italic>, prime agent of Madura foot, to tea tree oil and artemisinin</article-title>. <source>J Antimicrob Chemother</source>. <year>2007</year>;<volume>59</volume>:<fpage>553</fpage>-<lpage>555</lpage>.</citation>
</ref>
<ref id="bibr68-1534734612438549">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van</surname><given-names>de</given-names></name>
<name><surname>Sande</surname><given-names>WW</given-names></name>
<name><surname>Fahal</surname><given-names>AH</given-names></name>
<name><surname>Bakker-Woudenberg</surname><given-names>IAJM</given-names></name>
<name><surname>van Belkum</surname><given-names>A</given-names></name>
</person-group>. <article-title><italic>Madurella mycetomatis</italic> is not susceptible to the echinocandin class of antifungal agents</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2010</year>;<volume>54</volume>:<fpage>2738</fpage>-<lpage>2740</lpage>.</citation>
</ref>
<ref id="bibr69-1534734612438549">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ameen</surname><given-names>M</given-names></name>
<name><surname>Arenas</surname><given-names>R</given-names></name>
</person-group>. <article-title>Emerging therapeutic regimes for the management of mycetomas</article-title>. <source>Expert Opin Pharmacother</source>. <year>2008</year>;<volume>9</volume>:<fpage>2077</fpage>-<lpage>2085</lpage>.</citation>
</ref>
<ref id="bibr70-1534734612438549">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fahal</surname><given-names>A</given-names></name>
<name><surname>El Toum</surname><given-names>E</given-names></name>
<name><surname>El Hassan</surname><given-names>A</given-names></name>
<name><surname>Mahgoub</surname><given-names>E</given-names></name>
<name><surname>Gumaa</surname><given-names>S</given-names></name>
</person-group>. <article-title>A preliminary study on the ultrastructure of <italic>Actinomadura pelletieri</italic> and its host tissue reaction</article-title>. <source>J Med Vet Mycol</source>. <year>1994</year>;<volume>32</volume>:<fpage>343</fpage>-<lpage>348</lpage>.</citation>
</ref>
<ref id="bibr71-1534734612438549">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramam</surname><given-names>M</given-names></name>
<name><surname>Garg</surname><given-names>T</given-names></name>
<name><surname>D’Souza</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>A two-step schedule for the treatment of actinomycotic mycetomas</article-title>. <source>Acta Dermato Venereologica</source>. <year>2000</year>;<volume>80</volume>(<issue>5</issue>):<fpage>378</fpage>-<lpage>380</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>